Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2012. The report details the results of an initial tender offer for Human Genome Sciences (HGS) and the commencement of a subsequent offering period to acquire the remaining shares.
Key Financial Metrics and Transaction Details
- Offer Price: US$14.25 per share in cash.
- Transaction Valuation: Approximately US$3.6 billion on an equity basis, or approximately US$3 billion net of cash and debt.
- Shares Acquired (Initial): Approximately 158,607,627 shares validly tendered and not withdrawn.
- Ownership Stake: The initial tender, combined with shares already beneficially owned by GSK, represents approximately 79% of HGS' outstanding shares.
- Additional Tendered Shares: 9,155,762 shares (approximately 4%) were tendered subject to guaranteed delivery procedures.
Material Changes and Transaction Progress
The initial tender offer expired on July 27, 2012. GSK has accepted all validly tendered shares. A subsequent offering period was initiated for four business days, expiring on August 2, 2012, to allow remaining stockholders to tender shares at the same price of US$14.25 per share without withdrawal rights.
GSK holds a top-up option to purchase newly-issued shares if necessary to reach at least 90% ownership. If GSK owns more than approximately 83% but less than 90% following the subsequent offering period, it plans to exercise this option.
Outlook, Management Commentary, and Risks
Merger Plan: GSK is obligated to effectuate a merger of its wholly-owned subsidiary with HGS. Upon effectiveness, remaining shares not tendered will convert to the right to receive US$14.25 in cash. HGS common stock will cease trading on NASDAQ.
Short-Form Merger: If GSK owns at least 90% of outstanding shares following the subsequent offering period and potential top-up option exercise, it expects to consummate a short-form merger.
Risks: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks and uncertainties, including those related to the business combination, future financial results, and operational plans. Specific risk factors are referenced in GSK's 2011 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the final percentage of HGS shares tendered after the subsequent offering period concludes on August 2, 2012.
- Confirm whether GSK exercises the top-up option to reach the 90% threshold required for a short-form merger.
- Review the Schedule TO filed with the SEC for full terms and conditions of the offer.
- Monitor the cessation of HGS trading on NASDAQ and the final cash payout to remaining shareholders.